Alnylam Pharmaceuticals ALNY Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's investing cash flow?
- Alnylam Pharmaceuticals (ALNY) reported investing cash flow of -$363.46M in Q2 2026.
- How has Alnylam Pharmaceuticals's investing cash flow changed year-over-year?
- Alnylam Pharmaceuticals's investing cash flow decreased by 157.1% year-over-year, from -$141.38M to -$363.46M.
- What is the long-term trend for Alnylam Pharmaceuticals's investing cash flow?
- Over 2 years (2021 to 2025), Alnylam Pharmaceuticals's investing cash flow has grown at a 31.6% compound annual growth rate (CAGR), from -$273.3M to $473.5M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.